Home/Filings/4/0001492422-26-000042
4//SEC Filing

Deschatelets Pascal 4

Accession 0001492422-26-000042

CIK 0001492422other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 4:16 PM ET

Size

4.5 KB

Accession

0001492422-26-000042

Research Summary

AI-generated summary of this filing

Updated

Apellis (APLS) CSO Pascal Deschatelets Sells 909 Shares

What Happened

  • Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals (APLS), sold 909 shares on January 20, 2026 at $19.79 per share, generating proceeds of $17,992. The filing indicates the sale was to cover tax withholding on Restricted Stock Units released January 16, 2026.

Key Details

  • Transaction date and price: 2026-01-20, 909 shares at $19.79 each.
  • Total proceeds: $17,992.
  • Shares owned after transaction: Not specified in the provided filing.
  • Transaction code: S (sale); footnote F1: sale made to cover tax withholding on RSUs released 1/16/2026.
  • Filing date: 2026-01-21 (appears timely based on the reported transaction date).

Context

  • Sales to cover tax withholding on RSU vesting are routine and typically administrative (not a direct signal of confidence or lack thereof in the company). This was not an option exercise or a purchase; it was a disposal to satisfy taxes.

Insider Transaction Report

Form 4
Period: 2026-01-20
Deschatelets Pascal
Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-01-20$19.79/sh909$17,9921,157,310 total
Footnotes (1)
  • [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets|2026-01-21

Issuer

Apellis Pharmaceuticals, Inc.

CIK 0001492422

Entity typeother

Related Parties

1
  • filerCIK 0001657720

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 4:16 PM ET
Size
4.5 KB